Novo Holdings, OrbiMed, and F-Prime Capital led a $100 million Series A financing round in OnCusp Therapeutics.

Private equity firms Novo Holdings, OrbiMed, and F-Prime Capital led a $100 million Series A financing round in OnCusp Therapeutics, a biopharmaceutical company, with participation from Sofinnova Investments, Catalio Capital Management, Marshall Wace, Forge Life Science Partners, Blackbird BioVentures, CJNV BioVenture and BioTrack Capital. "We are grateful to have the trust and support from some of the most prominent global biotech investors. I am also thankful to the OnCusp team for their commitment and excellent work. We hold a strong conviction to develop innovative oncology therapies for patients. This significant Series A financing enables OnCusp to accelerate the development of CUSP06 and other game-changing therapeutics in our fight against cancer," Bing Yuan, OnCusp Therapeutics Co-Founder and CEO.